StockMacro
Menu

Royalty Pharma

$68.45 +27% in 6 monthsMarket cap $30.5B

RPRX on XNAS, Health Care, Royalty Pharma plc, job postings

Measures activity, not value. Not investment advice.

Shares up 78% in a year, but insiders sold $32.6M in 90 days and bought nothing.

  • GoodInstitutional holders rose to 695 from 633, up 9.8%
  • WatchNet income fell 12% to $671.5M despite revenue up 11%

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Industry
Pharmaceutical preparations (Health Care)
Employees
100
Website
royaltypharma.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 10 Feb 2027 (an estimate: a year ago it reported on 11 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $690.1M, net income $144.7M.
Quarter to 31 Dec 2021: revenue $575.7M, net income $7.9MQuarter to 31 Dec 2021: revenue $575.7M, net income $7.9MQuarter to 31 Mar 2022: revenue $562.0M, net income $51.8MQuarter to 31 Mar 2022: revenue $562.0M, net income $51.8MQuarter to 30 Jun 2022: revenue $536.0M, net income $304.5MQuarter to 30 Jun 2022: revenue $536.0M, net income $304.5MQuarter to 30 Sep 2022: revenue $573.5M, net income $142.7MQuarter to 30 Sep 2022: revenue $573.5M, net income $142.7MQuarter to 31 Dec 2022: revenue $565.7M, net income -$456.1MQuarter to 31 Dec 2022: revenue $565.7M, net income -$456.1MQuarter to 31 Mar 2023: revenue $684.0M, net income $340.8MQuarter to 31 Mar 2023: revenue $684.0M, net income $340.8MQuarter to 30 Jun 2023: revenue $538.2M, net income $227.6MQuarter to 30 Jun 2023: revenue $538.2M, net income $227.6MQuarter to 30 Sep 2023: revenue $536.3M, net income $72.1MQuarter to 30 Sep 2023: revenue $536.3M, net income $72.1MQuarter to 31 Dec 2023: revenue $596.1M, net income $494.3MQuarter to 31 Dec 2023: revenue $596.1M, net income $494.3MQuarter to 31 Mar 2024: revenue $568.0M, net income $4.8MQuarter to 31 Mar 2024: revenue $568.0M, net income $4.8MQuarter to 30 Jun 2024: revenue $537.3M, net income $102.0MQuarter to 30 Jun 2024: revenue $537.3M, net income $102.0MQuarter to 30 Sep 2024: revenue $564.7M, net income $544.0MQuarter to 30 Sep 2024: revenue $564.7M, net income $544.0MQuarter to 31 Dec 2024: revenue $593.6M, net income $208.2MQuarter to 31 Dec 2024: revenue $593.6M, net income $208.2MQuarter to 31 Mar 2025: revenue $568.2M, net income $238.3MQuarter to 31 Mar 2025: revenue $568.2M, net income $238.3MQuarter to 30 Jun 2025: revenue $578.7M, net income $30.2MQuarter to 30 Jun 2025: revenue $578.7M, net income $30.2MQuarter to 30 Sep 2025: revenue $609.3M, net income $288.2MQuarter to 30 Sep 2025: revenue $609.3M, net income $288.2MQuarter to 31 Dec 2025: revenue $622.0M, net income $214.2MQuarter to 31 Dec 2025: revenue $622.0M, net income $214.2MQuarter to 31 Mar 2026: revenue $630.6M, net income $294.7MQuarter to 31 Mar 2026: revenue $630.6M, net income $294.7MQuarter to 30 Jun 2026: revenue $674.1M, net income $17.9MQuarter to 30 Jun 2026: revenue $674.1M, net income $17.9MQuarter to 30 Sep 2026: revenue $690.1M, net income $144.7MQuarter to 30 Sep 2026: revenue $690.1M, net income $144.7M
31 Dec 2021RevenueNet incomeNet losstallest bar $690.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$690.1M$144.7M
30 Jun 2026$674.1M$17.9M
31 Mar 2026$630.6M$294.7M
31 Dec 2025$622.0M$214.2M
30 Sep 2025$609.3M$288.2M
30 Jun 2025$578.7M$30.2M
31 Mar 2025$568.2M$238.3M
31 Dec 2024$593.6M$208.2M
30 Sep 2024$564.7M$544.0M
30 Jun 2024$537.3M$102.0M
31 Mar 2024$568.0M$4.8M
31 Dec 2023$596.1M$494.3M
30 Sep 2023$536.3M$72.1M
30 Jun 2023$538.2M$227.6M
31 Mar 2023$684.0M$340.8M
31 Dec 2022$565.7M-$456.1M
30 Sep 2022$573.5M$142.7M
30 Jun 2022$536.0M$304.5M
31 Mar 2022$562.0M$51.8M
31 Dec 2021$575.7M$7.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $2.6B $2.3B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +11% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $671.5M $764.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $1.53 $1.75
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 57.1% 65.2% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 25.7% 32.5% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 6.9% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $544.9M $955.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $8.6B $8.9B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $8.0B $8.0B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.88 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 45.4 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 11.6 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 14.7 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.1 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Royalty PharmaRPRX (this company) $30.5B45.411.6+11%25.7%
InsmedINSM $31.0Bloss20.4+240%-39.9%
ZoetisZTS $32.1B12.93.4+1.0%26.1%
Roivant SciencesROIV $28.0Bloss682–-838%
United TherapeuticsUTHR $23.6B19.27.4+1.9%38.6%
ViatrisVTRS $22.5Bloss1.5+4.3%-4.1%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$32.6M

bought $0, sold $32.6M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+9.8%

695 13F filers vs 633

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

–

No 13F holdings or share count.

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

–

13.1M shares sold short (30 Oct 2026); no share count in the company's filings in our data

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.0

13.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+1.8%

12.8M shares sold short in the report before, 13.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

60%

60% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 43%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+13%

$690.1M vs $609.3M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

31

31 articles in the last 7 days; its usual week has 4.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

6.9×

31 articles in the last 7 days; its usual week has 4.5.

Price $68.45 on 20 Nov 2026, +78% over 12 months (12-month range $38.09 to $70.01)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $108.5M in the last 12 months (the 12 months before: -$11.8M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $690.1M in the latest quarter, +13% on a year earlier.
Institutional holders (13F filers). 695 13F filers reported holding it in the latest 13F quarter, +49% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
22 Dec 20258-K and other filingsDirector or officer change
22 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Aug 20258-K and other filingsDirector or officer change
17 Jul 20258-K and other filingsDirector or officer change
1 Jul 2025Sharp changeShort interest spike: short interest spike, 29.0M vs usual 15.6M (2025-06-13); 1.9x the same period a year earlier
17 Jun 2025Sharp changeShort interest spike: short interest spike, 29.0M vs usual 15.6M (2025-05-30); 2.2x the same period a year earlier
19 May 20258-K and other filingsDirector or officer change
19 May 20258-K and other filingsCompleted an acquisition or asset sale
29 Apr 2025Sharp changeShort interest spike: short interest spike, 20.6M vs usual 14.8M (2025-04-15); 1.5x the same period a year earlier
10 Apr 20258-K and other filingsDirector or officer change
10 Apr 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Dec 20228-K and other filingsAsset write-down (impairment)
4 Apr 20228-K and other filingsChanged its auditor
Insider net buying (open market)
Month from 1 Dec 2021: -$7.4M published
Month from 1 Feb 2022: $1.2M published
Month from 1 Mar 2022: -$9.0M published
Month from 1 May 2022: -$13.9M published
Month from 1 Jun 2022: -$13.5M published
Month from 1 Jul 2022: -$4.3M published
Month from 1 Aug 2022: -$4.5M published
Month from 1 Sep 2022: -$149.5M published
Month from 1 Oct 2022: -$5.5M published
Month from 1 Nov 2022: -$10.3M published
Month from 1 Dec 2022: -$22.1M published
Month from 1 Feb 2023: -$1.8M published
Month from 1 Mar 2023: -$9.3M published
Month from 1 May 2023: -$44.9M published
Month from 1 Jun 2023: $317K published
Month from 1 Jul 2023: -$2.3M published
Month from 1 Aug 2023: -$2.3M published
Month from 1 Dec 2023: -$26.8M published
Month from 1 Jan 2024: -$15.1M published
Month from 1 Aug 2025: -$1.2M published
Month from 1 Nov 2025: -$10.6M published
Month from 1 Dec 2025: -$19.7M published
Month from 1 Jan 2026: -$8.6M published
Month from 1 Feb 2026: -$12.8M published
Month from 1 Mar 2026: -$3.2M published
Month from 1 Apr 2026: -$1.7M published
Month from 1 May 2026: -$6.8M published
Month from 1 Jun 2026: -$8.7M published
Month from 1 Jul 2026: -$7.9M published
Month from 1 Aug 2026: -$6.6M published
Month from 1 Sep 2026: -$5.9M published
Month from 1 Oct 2026: -$474K published
Month from 1 Nov 2026: -$26.2M published
H-1B/E-3 applications certified
Quarter from 1 Jul 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $575.7M, +0.6% on a year earlier; public on 16 Feb 2022
Quarter ended 31 Mar 2022: $562.0M, -1.9% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $536.0M, -3.4% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $573.5M, -2.1% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $565.7M, -1.7% on a year earlier; public on 16 Feb 2023
Quarter ended 31 Mar 2023: $684.0M, +22% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $538.2M, +0.4% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $536.3M, -6.5% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $596.1M, +5.4% on a year earlier; public on 16 Feb 2024
Quarter ended 31 Mar 2024: $568.0M, -17% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $537.3M, -0.2% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $564.7M, +5.3% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $593.6M, -0.4% on a year earlier; public on 13 Feb 2025
Quarter ended 31 Mar 2025: $568.2M, 0% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $578.7M, +7.7% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $609.3M, +7.9% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $622.0M, +4.8% on a year earlier; public on 12 Feb 2026
Quarter ended 31 Mar 2026: $630.6M, +11% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $674.1M, +16% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $690.1M, +13% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 236; public on 14 Feb 2022
31 Mar 2022 report: 261; public on 16 May 2022
30 Jun 2022 report: 264; public on 15 Aug 2022
30 Sep 2022 report: 285; public on 14 Nov 2022
31 Dec 2022 report: 303; public on 14 Feb 2023
31 Mar 2023 report: 312; public on 15 May 2023
30 Jun 2023 report: 300; public on 14 Aug 2023
30 Sep 2023 report: 287; public on 14 Nov 2023
31 Dec 2023 report: 339; public on 14 Feb 2024
31 Mar 2024 report: 363; public on 15 May 2024
30 Jun 2024 report: 360; public on 14 Aug 2024
30 Sep 2024 report: 374; public on 14 Nov 2024
31 Dec 2024 report: 397; public on 14 Feb 2025
31 Mar 2025 report: 430; public on 15 May 2025
30 Jun 2025 report: 434; public on 14 Aug 2025
30 Sep 2025 report: 468; public on 14 Nov 2025
31 Dec 2025 report: 514; public on 17 Feb 2026
31 Mar 2026 report: 571; public on 15 May 2026
30 Jun 2026 report: 633; public on 14 Aug 2026
30 Sep 2026 report: 695; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $26.2M (18 Nov 2026), 15× its normal reading; higher than 92% of its own history.
  • Insider net buying (open market): Insiders sold a net $108.5M in the last 12 months (the 12 months before: -$11.8M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
  • Revenue per quarter: Revenue $690.1M in the latest quarter, +13% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 6 sales, $32.6M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Christopher HiteEVP & Chairman, PartneringSellplanned in advance (10b5-1)100,000$68.15$6.8MForm 4
18 Nov 2026Terrance P. CoyneEVP & CFOSellplanned in advance (10b5-1)257,122$68.81$17.7MForm 4
18 Nov 2026Marshall UristEVP, Research & InvestmentsSellplanned in advance (10b5-1)25,000$69.50$1.7MForm 4
5 Oct 2026Marshall UristEVP, Research & InvestmentsSellplanned in advance (10b5-1)4,126$57.10$236KForm 4
30 Sep 2026Marshall UristEVP, Research & InvestmentsSellplanned in advance (10b5-1)4,126$57.88$239KForm 4
24 Sep 2026Christopher HiteEVP & Chairman, PartneringSellplanned in advance (10b5-1)100,000$58.53$5.9MForm 4
19 Aug 2026Christopher HiteEVP & Chairman, PartneringSellplanned in advance (10b5-1)100,000$59.97$6.0MForm 4
17 Aug 2026Terrance P. CoyneEVP & CFOSellplanned in advance (10b5-1)11,002$58.68$646KForm 4

695 institutions reported shares at the end of Q3 2026, 96% of the shares outstanding; 105 opened a position, 45 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Morgan Stanley41.1M10.6%$2.4B-1.8M-4.3%
Capital International Investors33.9M8.73%$2.0B-1.4M-3.9%
BlackRock, Inc.29.1M7.50%$1.7B+1.3M+4.6%
FMR LLC (Fidelity)19.3M4.99%$1.1B-5.2M-21%
T. Rowe Price Associates Inc14.7M3.79%+3.5M+31%
State Street Corp13.0M3.34%$755.9M+613K+5.0%
Swedbank AB10.3M2.64%$598.8M-466K-4.3%
Baillie Gifford & Co9.2M2.36%$534.1M-864K-8.6%
Capital World Investors8.8M2.26%$511.0M-762K-8.0%
Geode Capital Management, LLC8.5M2.20%$497.5M+489K+6.1%

Company events

All 29 company events

In 12 months: 1 director or officer change, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
28 May 2026Signed a major agreementSame filing: took on new debt8-K
22 Dec 2025Director or officer change8-K
16 Sep 2025Signed a major agreement8-K
13 Aug 2025Director or officer change8-K
17 Jul 2025Director or officer change8-K
19 May 2025Director or officer change; Signed a major agreement; Completed an acquisition or asset saleSame filing: took on new debt, changed its bylaws or fiscal year8-K
11 Apr 2025Signed a major agreement8-K
10 Apr 2025Director or officer change8-K

Reported lobbying spend: $150K in Q2 2014, $200K in Q1 2014. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Jun 2014EndedBen Barnes Group LPfor Royalty Pharma - / RP Management, LLCTax Reform, Limited PartnershipTaxation, MED, Science/technologyFiling
1 Apr 2012NewBen Barnes Group LPfor Royalty Pharma - / RP Management, LLCCorrect publicly traded partnership rules on passive incomeTaxation, MED, Science/technologyFiling
Timeline

Timeline

Changes and notable records, by the date each became public

  1. 13 May 2026Institutional holdings record

    Capital World Investors opened a $386.0M position (2026Q1 13F)

  2. 22 Dec 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 22 Dec 2025Filings record

    Director or officer change

  4. 13 Aug 2025Institutional holdings record

    Capital International Investors opened a $788.0M position (2025Q2 13F)

  5. 13 Aug 2025Filings record

    Director or officer change

  6. 17 Jul 2025Filings record

    Director or officer change

  7. 26 Jun 2025Short interest and volume change

    had 29.0M shares sold short in the 13 Jun 2025 report, 1.9× the same report last year.

    Same report last year: 15.5M; its normal report is 15.6M.

    See the evidence
    This period
    29.0M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    15.6M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +8.6
    Same report last year
    15.5M
    History used
    2,723 days
    2024-06-14: 15.5M2024-06-28: 16.9M2024-07-15: 16.5M2024-07-31: 14.9M2024-08-15: 14.3M2024-08-30: 14.7M2024-09-13: 14.2M2024-09-30: 14.6M2024-10-15: 14.5M2024-10-31: 14.6M2024-11-15: 14.7M2024-11-29: 15.7M2024-12-13: 15.6M2024-12-31: 16.6M2025-01-15: 16.6M2025-01-31: 16.1M2025-02-14: 15.3M2025-02-28: 13.8M2025-03-14: 15.6M2025-03-31: 18.0M2025-04-15: 20.6M2025-04-30: 18.6M2025-05-15: 20.7M2025-05-30: 29.0M2025-06-13: 29.0M
    the 13 Jun 2025 report24 earlier reportsnormal: 15.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 11 Jun 2025Short interest and volume change

    had 29.0M shares sold short in the 30 May 2025 report, 2.2× the same report last year.

    Same report last year: 13.2M; its normal report is 15.6M.

    See the evidence
    This period
    29.0M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    15.6M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +8.7
    Same report last year
    13.2M
    History used
    2,709 days
    2024-05-31: 13.2M2024-06-14: 15.5M2024-06-28: 16.9M2024-07-15: 16.5M2024-07-31: 14.9M2024-08-15: 14.3M2024-08-30: 14.7M2024-09-13: 14.2M2024-09-30: 14.6M2024-10-15: 14.5M2024-10-31: 14.6M2024-11-15: 14.7M2024-11-29: 15.7M2024-12-13: 15.6M2024-12-31: 16.6M2025-01-15: 16.6M2025-01-31: 16.1M2025-02-14: 15.3M2025-02-28: 13.8M2025-03-14: 15.6M2025-03-31: 18.0M2025-04-15: 20.6M2025-04-30: 18.6M2025-05-15: 20.7M2025-05-30: 29.0M
    the 30 May 2025 report24 earlier reportsnormal: 15.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 19 May 2025Filings record

    Director or officer change

  10. 19 May 2025Filings record

    Completed an acquisition or asset sale

  11. 26 Apr 2025Short interest and volume change

    had 20.6M shares sold short in the 15 Apr 2025 report, 1.5× the same report last year.

    Same report last year: 14.2M; its normal report is 14.8M.

    See the evidence
    This period
    20.6M (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    14.8M
    Typical spread (median absolute deviation)
    833K
    How far from its usual level
    +3.9
    Same report last year
    14.2M
    History used
    2,664 days
    2024-04-15: 14.2M2024-04-30: 13.7M2024-05-15: 13.3M2024-05-31: 13.2M2024-06-14: 15.5M2024-06-28: 16.9M2024-07-15: 16.5M2024-07-31: 14.9M2024-08-15: 14.3M2024-08-30: 14.7M2024-09-13: 14.2M2024-09-30: 14.6M2024-10-15: 14.5M2024-10-31: 14.6M2024-11-15: 14.7M2024-11-29: 15.7M2024-12-13: 15.6M2024-12-31: 16.6M2025-01-15: 16.6M2025-01-31: 16.1M2025-02-14: 15.3M2025-02-28: 13.8M2025-03-14: 15.6M2025-03-31: 18.0M2025-04-15: 20.6M
    the 15 Apr 2025 report24 earlier reportsnormal: 14.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 10 Apr 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 10 Apr 2025Filings record

    Director or officer change

  14. 29 Jun 2023Insiders record

    Legorreta Pablo G. (CEO, Chairman of the Board) bought 130,000 shares of RPRX ($3.8M) (dated 28 Jun 2023)

  15. 14 Jun 2023Insiders record

    Legorreta Pablo G. (CEO, Chairman of the Board) bought 90,000 shares of RPRX ($3.0M) (dated 13 Jun 2023)

  16. 25 May 2023Insiders record

    Legorreta Pablo G. (CEO, Chairman of the Board) bought 150,000 shares of RPRX ($4.8M) (dated 24 May 2023)

  17. 18 May 2023Insiders record

    Legorreta Pablo G. (CEO, Chairman of the Board) bought 230,000 shares of RPRX ($7.7M) (dated 17 May 2023)

  18. 1 Dec 2022Filings record

    Asset write-down (impairment)

  19. 4 Apr 2022Filings record

    Changed its auditor

  20. 26 Feb 2022Insiders record

    Fernandez Henry A (director) bought 32,500 shares of RPRX ($1.2M) (dated 25 Feb 2022)

  21. 15 Nov 2021Institutional holdings record

    Berkshire Hathaway Inc opened a $475.0M position (2021Q3 13F)

  22. 15 Apr 2021Institutional holdings record

    DnB Asset Management AS opened a $695.0M position (2021Q1 13F)

  23. 27 Feb 2021Insiders record

    Fernandez Henry A (director) bought 25,700 shares of RPRX ($1.2M) (dated 26 Feb 2021)

  24. 13 Oct 2020Filings record

    Registered new securities for sale (S-1)

  25. 14 Aug 2020Institutional holdings record

    Capital International Investors opened a $395.0M position (2020Q2 13F)

  26. 14 Aug 2020Institutional holdings record

    ADAGE CAPITAL PARTNERS GP, L.L.C. opened a $2.2B position (2020Q2 13F)

  27. 14 Aug 2020Institutional holdings record

    WELLINGTON MANAGEMENT GROUP LLP opened a $272.0M position (2020Q2 13F)

  28. 14 Aug 2020Institutional holdings record

    MORGAN STANLEY opened a $301.0M position (2020Q2 13F)

  29. 14 Aug 2020Institutional holdings record

    PRICE T ROWE ASSOCIATES INC /MD/ opened a $389.0M position (2020Q2 13F)

  30. 13 Aug 2020Institutional holdings record

    FMR LLC opened a $743.0M position (2020Q2 13F)

  31. 3 Aug 2020Filings record

    Director or officer change

  32. 24 Jun 2020Insiders record

    RIGGS RORY B (director) bought 15,000 shares of RPRX ($420,000) (dated 23 Jun 2020)

  33. 24 Jun 2020Insiders record

    Coyne Terrance P. (EVP & CFO) bought 2,950 shares of RPRX ($82,600) (dated 23 Jun 2020)

  34. 24 Jun 2020Insiders record

    Hite Christopher (EVP & Vice Chairman) bought 70,000 shares of RPRX ($2.0M) (dated 23 Jun 2020)

  35. 23 Jun 2020Insiders change

    had 5 insiders buy $128.4M of its shares on the open market within 30 days (5 filings).

    Who bought: Ford William E, Lloyd George W., Legorreta Pablo G..

    See the evidence (5 source records)
    Independent buyers
    5
    Purchase filings (Form 4, code P)
    5
    Total bought
    $128.4M
    Window
    24 May 2020 to 23 Jun 2020

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  36. 23 Jun 2020Insiders record

    Legorreta Pablo G. (CEO, Chairman of the Board) bought 20,000 shares of RPRX ($560,000) (dated 22 Jun 2020)

  37. 23 Jun 2020Insiders record

    Giuliani Mario Germano (director) and 4 other(s) bought 50,000 shares of RPRX ($1.4M) (dated 22 Jun 2020)

  38. 23 Jun 2020Insiders record

    Lloyd George W. (EVP, Investments & GC) bought 14,200 shares of RPRX ($397,600) (dated 22 Jun 2020)

  39. 23 Jun 2020Insiders record

    ADAGE CAPITAL PARTNERS GP, L.L.C. (ten percent owner) and 4 other(s) bought 3,000,000 shares of RPRX ($84.0M) (dated 22 Jun 2020)

  40. 23 Jun 2020Insiders record

    FORD WILLIAM E (director) bought 1,500,000 shares of RPRX ($42.0M) (dated 22 Jun 2020)

Showing the newest 40 of 48 entries; narrow the window or the kind of data to see older ones.

Not listed: 213 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001802768
Ticker
RPRX
Domain
royaltypharma.com
Employer name
Royalty Pharma, LLC (1 unverified)
Fein
33-4368057 (1 unverified)
Hq location
NY|NEW YORK|10022 (1 unverified)
Lobbying client
royalty pharma rp management
Name
Legal Name of Subsidiary, Royalty Pharma Development Funding, LLC, Royalty Pharma Holdings Ltd, Royalty Pharma Investments 2011 ICAV and 6 more
Wikipedia
Royalty Pharma
  • DOL H-1B labor condition applications and PERM certifications5 data points27 Apr 2026 to 27 Apr 2026
  • Federal lobbying disclosures (LDA)2 records, 27 data points1 Apr 2012 to 30 Jun 2014
  • SEC Form 13F institutional holdings10 records, 234 data points30 Jun 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)100 records22 May 2020 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)401 data points31 Dec 2017 to 30 Sep 2026
  • SEC Form 4 insider transactions142 records, 404 data points22 Jun 2020 to 18 Nov 2026
  • FINRA short interest (twice monthly)464 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3236 data points16 Jun 2020 to 20 Nov 2026
  • Wikipedia pageviews10 data points11 Nov 2026 to 20 Nov 2026